TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02633748

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Mindfulness-Based Cancer Survivorship
Description: Mindfulness-Based Cancer Survivorship (MBCS) is a four-week standardized mindfulness program, adapted for cancer survivors from Mindfulness-Based Stress Reduction (MBSR). MBCS teaches formal mindfulness practice (meditation) and informal mindfulness during daily activities. Mindfulness has been shown to help stress, fatigue, sleep complaints, and other symptoms but has not been extensively studied in cancer survivors.
Study: NCT01105871

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: naloxone
Description: 4 mg naloxone in 10 ml saline given iv bolus

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 10 ml of normal saline iv bolus
Study: NCT04198259

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: interventional devascularization
Description: Interventional devascularization (BRTO and its variations) is a procedure for treatment of fundal varices associated with a large gastro-/splenorenal collateral.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TIPS
Description: TIPS is very effective in the treatment of bleeding GV, with more than a 90% success rate for initial hemostasis. It frequently requires additional embolization of spontaneous collaterals feeding the varices. The incidence of encephalopathy was higher after TIPS.
Study: NCT03531138

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pulmonary Rehabilitation
Description: All patients will undergo supervised pulmonary rehabilitation program on 2 days per week for 3 months. Apart from that, they will ask to perform the home exercise program which is scheduled as 3 days per week and fill out the exercise follow-up form. Supervised exercise sessions consist of aerobic(treadmill walking, bicycle training, arm ergometer training) and strengthening training(free weights). A 6-min walk test, a 10-meter walking speed test and a 5 times sit to stand test will be performed to determine the exercise capacity of the patient. The tests will be carried out at the beginning and end of rehabilitation. At each testing session, the tests will be performed sequentially by the same physiotherapist, giving 20 minute rest periods within the same day.
Study: NCT00339144

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: tablets, Oral, 100 mg, once daily for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: tablets, Oral, 150 mg, once daily, 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: tablets, Oral, 200 mg, once daily for 4 weeks
Study: NCT02523014

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vismodegib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FAK Inhibitor GSK2256098
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capivasertib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Given PO
Study: NCT05019599

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: low protein diet
Description: Low protein diet (\<0.8g/kg/BW/day)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: low protein diet
Description: Low protein diet (\<0.8g/kg/BW/day)
Study: NCT03944941

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Avelumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Given IV
Study: NCT03975231

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib
Description: Given PO

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-Modulated Radiation Therapy
Description: Undergo IMRT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Given PO
Study: NCT01952314

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naftopidil 75mg
Description: naftopidil 75mg 1T qd hs

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Naftopidil
Description: Placebo 1T qd hs

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Standard treatment
Description: Aceclofenac 100mg or tramadol37.5mg/acetaminophen 325mg on demand

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard treatment
Description: Aceclofenac 100mg or tramadol37.5mg/acetaminophen 325mg on demand
Study: NCT02079181

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: computed tomography
Description: Undergo fluorine F 18 d-FMAU PET/CT scan
Study: NCT00484393

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tetracaine 4% gel
Description: tetracaine applied prior to 1 injection
Study: NCT03134092

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Probabilistic Risk Communication Tool (PRT)
Description: The probabilistic risk communication tool (PRT) is a visual tool that communicates risk using the previously validated Opioid Risk Tool (ORT). The ORT is designed to assess risk of opioid dependency for patients for whom an opioid pain relief prescription is being considered in outpatient settings. Patients in this arm will be given an iPad which will prompt them to take a short survey that automatically communicates their risk score. After which the iPad will show them a color coded visual thermometer that informs them of their risk of having issues related to opioids.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Probabilistic Risk Communication Tool (PRT)
Description: The probabilistic risk communication tool (PRT) is a visual tool that communicates risk using the previously validated Opioid Risk Tool (ORT). The ORT is designed to assess risk of opioid dependency for patients for whom an opioid pain relief prescription is being considered in outpatient settings. Patients in this arm will be given an iPad which will prompt them to take a short survey that automatically communicates their risk score. After which the iPad will show them a color coded visual thermometer that informs them of their risk of having issues related to opioids.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Narrative Enhanced Risk Tool (NERT)
Description: Participants assigned to this arm will receive the PRT described above but will also be instructed to watch one or more narrative videos. This video intervention will include a brief narrative video of an individuals' cautionary tale around prolonged opioid uses. Narrative videos are developed from actual patients sharing their stories - put into a in a structured format of \~ 2-minute length and recorded.
Study: NCT00380744

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2189102

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2189102

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2189102

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2189102

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT02191644

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Dietary intervention-refined rice
Description: Subjects in the control group maintained the usual refined-rice diet.
Study: NCT00484393

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo applied prior to 1 injection
Study: NCT05173948

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesio taping
Description: Kinesio taping: The tape is measured from the sacrum to the 12th thoracic vertebra with forwarding flexion of the trunk. The base is affixed to the insertion in the resting position. The muscle is elongated and the base anchored with skin displacement. The tape is then affixed with 10% stretch paravertebrally over the muscle bundles up to T12. The tape is rubbed with the muscle in the elongated state.
Study: NCT02191644

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary intervention-whole grains and legumes
Description: Subjects in the whole-grain group replaced refined rice with a mix of 1/3 legumes, 1/3 barley, and 1/3 wild rice three times per day, and increased vegetable intake to at least 6 units (30-70 g/unit) per day for sufficient dietary fiber intake.
Study: NCT02525237

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Apatinib (500 mg qd p.o.) until disease progression or intolerable toxicity

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1
Description: S-1 (40 mg/m2 qd days 1-14 q3w p.o.) until disease progression or intolerable toxicity
Study: NCT01992718

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Evaluation of MRI, US for pelvic and uterine conditions
Description: Pelvic ultrasound with transabdominal and transvaginal imaging. The transvaginal ultrasound will include elastography (TVUS-E). Also, a pelvic MRI will be performed if not done in the last 6 months. The MRI is performed with IV gadolinium-based contrast (MultiHance ®).~A patient survey will be included.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Patient preference between MRI and Ultrasound
Description: Subjects may take part in this arm because they have recently had a MRI performed and scheduled for, or have recently undergone a pelvic ultrasound.~Subjects will also be asked to complete a survey that will state their preference with regards to examination/imaging. This will be done over the phone and will take no longer than 30 minutes to complete.
Study: NCT03289273

Intervention type: DRUG
Intervention: Regorafenib (Stivarga, BAY73-4506)
Description: As per the treating physicians discretion
Study: NCT03070782

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISIS 681257
Description: ISIS 681257 solution for SC injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISIS 681257
Description: ISIS 681257 solution for SC injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISIS 681257
Description: ISIS 681257 solution for SC injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISIS 681257
Description: ISIS 681257 solution for SC injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISIS 681257
Description: ISIS 681257 solution for SC injection.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sterile normal saline (0.9% NaCl)
Study: NCT00972569

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BNP and PDE-V
Description: low dose BNP 0.025 u/kg/min for 3 hours then 0.005ug/kg/min 45 hours PDE-V 12.5 mg 4 time points

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BNP
Description: low dose BNP at 0.025 u/kg/min if tolerated then at 0.005 ug/kg/min for 45 hours
Study: NCT05173948

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Conventional physical therapy
Description: Transcutaneous electrical nerve stimulation device settings, such as the frequency of 80 Hz, the pulse width of 100 µs, and symmetrical biphasic waveform. Four mediums sized (2 × 2 cm) carbon-impregnated rubber cutaneous electrodes were placed bilaterally in a standard dermatomal pattern over the most painful lumbar region. The current intensity was increased up to the patient's perception of paraesthesia. The supervised exercise therapy management consisted of stretching exercises for the back, iliopsoas, gluteal and hamstring muscles, and strengthening exercises for the abdominal and back muscles. Three sets of stretching exercises, each involving a 30-sec hold and 30-sec of rest repeated three times, were performed in three sessions per week over four weeks. One set of strengthening exercises, consisting of 10 repetitions with a 5-sec hold, was performed in three sessions per week over four weeks.
Study: NCT02319746

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy program to first-episode psychosis patients and cannabis abuse
Description: The intervention program is focused on reducing the cannabis use, improving awareness of illness, adherence to treatment, identification of prodromes, psychosocial functioning improvement and relapse prevention.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducation
Description: The aim of psychoeducation is that the patient understands and be able to manage the disease providing the tools and skills to symptoms management, to avoid relapse and contribute to their wellbeing.
Study: NCT01308346

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bioabsorbable Vascular Solutions Everolimus Eluting Coronary Stent System (BVS EECSS)
Description: Bioabsorbable Everolimus Eluting Coronary Stent

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: XIENCE V® Everolimus Eluting Coronary Stent System (EECSS)
Description: XIENCE V® Everolimus Eluting Coronary Stent System (EECSS)
Study: NCT02845622

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Hazelnut
Description: This dietary supplement contains 30 g of hazelnut.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Hazelnut
Description: This dietary supplement contains 30 g of hazelnut.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Hazelnut
Description: This dietary supplement contains 30 g of hazelnut.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Hazelnut
Description: This dietary supplement contains 30 g of hazelnut.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cocoa
Description: This dietary supplement contains 2.5 g of cocoa powder.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cocoa
Description: This dietary supplement contains 2.5 g of cocoa powder.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: No hazelnuts / No cocoa
Description: This dietary supplement does not contain hazelnut nor cocoa powder.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cream
Description: This dietary supplement is just a cream obtained by grinding hazelnuts.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cream
Description: This dietary supplement is just a cream obtained by grinding hazelnuts.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Snack
Description: This dietary supplement is a commercial snack containing either hazelnut or cocoa or both.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Snack
Description: This dietary supplement is a commercial snack containing either hazelnut or cocoa or both.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Snack
Description: This dietary supplement is a commercial snack containing either hazelnut or cocoa or both.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Snack
Description: This dietary supplement is a commercial snack containing either hazelnut or cocoa or both.
Study: NCT02715024

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamsulosin
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamsulosin
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solifenacin
Description: Oral
Study: NCT04251767

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: washed microbiota transplantation
Description: Washed microbiota suspension (5u) delivered through nasogastric tube, nasojejunal tube or oral.~Dose and frequency: 5u, once.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo (edible suspension of the same color as the washed microbiota suspension，5u) administered via nasogastric tube, nasojejunal tube or oral, combining with standard therapy.~Dose and frequency: 5u, once.
Study: NCT03155919

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: TAUchoc
Description: The supplements were offered during eight weeks in capsules containing three grams of taurine powder and 400 ml of chocolate milk ready to drink.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: PLAchoc
Description: The supplements were offered during eight weeks in capsules containing three grams of placebo (starch powder) and 400 ml of chocolate milk ready to drink.
Study: NCT01952548

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K-312

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K-312

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K-312

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K-312

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K-312

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K-312

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K-312

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03576066

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABI-H0731
Description: Participants will receive ABI-H0731 300 mg tablets orally once daily (QD).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOC NUC
Description: Participants will continue on their SOC NUC (ETV, TDF or TAF) tablet orally as per approved package insert.
Study: NCT01571427

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active social engagement group
Description: Engage in 30 minutes conversation daily using internet/webcam, 5 days per week for 6 weeks, tracking of daily conversational amount outside of the trial by using a digital recording device, lasting effects will be assessed at the 3rd and 6th month after completion of the intervention

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control group
Description: No active intervention, weekly phone calls by interviewer to complete health/social engagement monitoring survey, tracking of daily conversational amount by using a digital recording device. Participants will be reassessed at the 3rd and 6th month after completion of the intervention.
Study: NCT01030939

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB-649868
Description: In each of all cohorts, 18 subjects will be randomised in a 2:1 ratio to receive either SB-649868 or placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB-649868
Description: In each of all cohorts, 18 subjects will be randomised in a 2:1 ratio to receive either SB-649868 or placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB-649868
Description: In each of all cohorts, 18 subjects will be randomised in a 2:1 ratio to receive either SB-649868 or placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB-649868
Description: In each of all cohorts, 18 subjects will be randomised in a 2:1 ratio to receive either SB-649868 or placebo
Study: NCT02338414

Intervention type: DRUG
Group type: OTHER
Intervention: Romiplostim
Description: Subcutaneous Romiplostim (weekly injection) -\> if titrated with maintaining PLT count between 50-200 x 10\^9/L -\> Subcutaneous Romiplostim (biweekly injection)
Study: NCT03837106

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rehabilitation program
Description: 3-month rehabilitation program comprising exercise and education specific to musicians. The program will be supported by an online platform containing more than 50 exercise videos, narrated powerpoint presentations, informative videos, quizzes, and forums for communicating with a physiotherapist and for organizing group exercise sessions.
Study: NCT05782465

Intervention type: PROCEDURE
Intervention: Blood Collection, processing and analyses
Description: 20ml of blood will be drawn from study participant at the baseline visit for molecular analyses.

Intervention type: PROCEDURE
Intervention: Gastroscopy and biopsies collection
Description: Study participant will undergo gastroscopy with collection of gastric mucosal biopsies at the baseline visit to ascertain OLGIM status and for molecular analyses. Study participant will undergo surveillance gastroscopy for gastric cancer at years 2 and 4 to assess whether they have reached endpoint.

Intervention type: DIAGNOSTIC_TEST
Intervention: Urea Breath Test
Description: Study participant will fast for 6 hours or overnight before undergoing the Urea Breath Test (UBT) to test for current H. pylori infection. Breath collection will be performed before ingestion of 13C urea, and at specified time intervals after ingestion.
Study: NCT05012839

Intervention type: OTHER
Intervention: impact of COVID-19 on Health-Seeking Behaviors
Description: The impact of the coronavirus disease 2019 (COVID-19) pandemic on medical services is overwhelming due to limited medical resources. During its initial surge in 2020, Taiwan's government rapidly established diverse public actions, which helped maintain the medical supply without travel restrictions. However, whether the fear of being infected with COVID-19 interfered with health-seeking behavior (HSB) remains unclear. Therefore, this study aimed to elucidate whether acute complicated appendicitis (ACA) rates in adults were affected by the COVID-19 pandemic.

Intervention type: OTHER
Intervention: impact of COVID-19 on Health-Seeking Behaviors
Description: The impact of the coronavirus disease 2019 (COVID-19) pandemic on medical services is overwhelming due to limited medical resources. During its initial surge in 2020, Taiwan's government rapidly established diverse public actions, which helped maintain the medical supply without travel restrictions. However, whether the fear of being infected with COVID-19 interfered with health-seeking behavior (HSB) remains unclear. Therefore, this study aimed to elucidate whether acute complicated appendicitis (ACA) rates in adults were affected by the COVID-19 pandemic.
Study: NCT01923701

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: GF-CBT focuses on teaching emotional self-regulation, information processing, decision making strategies,and logical thinking skills. The program is comprised of three parts: 1) Group sessions in which adolescents receive social support from peers who have had similar experiences and learn CBT skills, 2) Family group sessions in which family members learn more about adolescents' experiences and learn CBT skills so that they can encourage and reinforce these skills at home, and 3) Individual sessions in which adolescents can apply CBT skills to their own lives and work toward personal goals. Group sessions are taught with Powerpoint slides and with an accompanying workbook.
Study: NCT01176669

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Apatinib was administratered at 750 mg/d in Phase IIa. The actual average dose intensity delivered was 525 mg/d due to toxicities. So, in Phase IIb, the starting dose of apatinib will be 500mg/d. Two dose reductions will be allowed to 375 and then 250 mg/d.